We further analyzed the immunological indicators between the two groups, and the results showed that the anti-RO52+ rate in pSS-ILD group was significantly higher than that in non-ILD group, while the positive rates of immunoglobulin and complement were not significantly different, indicating that anti-Ro52+ pSS patients were more prone to ILD. This evidence concerns the gene TRIM21 and interstitial lung disease.